Abstract

This concept note aims to define the methodological orientations of the project to draft this recommendation. Questions that will be addressed include:

  1. Regarding shingles vaccines:
      • Can the Shingrix vaccine be used to prevent shingles and its complications in immunocompetent adults over 50 (in terms of immunogenicity, clinical efficacy, safety)?
      • Can a preferential recommendation of one or other of the vaccines (Shingrix, Zostavax) be considered among the immunocompetent population?
      • Can the Shingrix vaccine be used to prevent shingles and its complications in immunocompromised patients from the age of 18 and according to which definition of immunosuppression (in terms of immunogenicity, clinical efficacy, safety)?
      • What data are available on the duration of protection conferred by the two vaccines? Is there a need for a booster and at what age, if so, can the Shingrix vaccine be used in people who have previously received the Zostavax vaccine?
      • What data is available on the co-administration of shingles vaccines with other adult vaccines included in the vaccination schedule (in terms of immunogenicity and safety)?
  2. Expected impact of the vaccine strategy:
      • What is the acceptability of shingles vaccination in the target populations?
      • What is the incremental cost-effectiveness of shingles vaccination?
      • What will be the impact in terms of quality of life, hospitalizations, incidence, functional independence, etc.?
      • Are the new data (in terms of public health and medico-economic impact) for these two vaccines likely to revise the age groups targeted by the current vaccination program?
  • Background paper
  • Europe
  • France
  • Herpes zoster